186 related articles for article (PubMed ID: 18699760)
1. Docetaxel in the treatment of advanced non-small-cell lung cancer.
Saloustros E; Georgoulias V
Expert Rev Anticancer Ther; 2008 Aug; 8(8):1207-22. PubMed ID: 18699760
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel in advanced non-small cell lung cancer.
Wakelee H; Ramalingam S; Belani CP
Expert Rev Anticancer Ther; 2005 Feb; 5(1):13-24. PubMed ID: 15757434
[TBL] [Abstract][Full Text] [Related]
3. The current status of docetaxel for advanced non-small cell lung cancer.
Green MR
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S11-6. PubMed ID: 11340898
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer.
Gandara DR; Edelman MJ; Lau D
Semin Oncol; 1999 Jun; 26(3 Suppl 10):3-7. PubMed ID: 10437743
[TBL] [Abstract][Full Text] [Related]
5. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
6. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Harper P
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.
Fossella FV
Semin Oncol; 1999 Oct; 26(5 Suppl 16):17-23; discussion 41-2. PubMed ID: 10585004
[TBL] [Abstract][Full Text] [Related]
8. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Fossella FV
Semin Oncol; 1999 Jun; 26(3 Suppl 11):4-8. PubMed ID: 10458203
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Miller VA; Kris MG
Semin Oncol; 2000 Apr; 27(2 Suppl 3):3-10. PubMed ID: 10810932
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme?
Armand JP
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():223-30. PubMed ID: 10895158
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
13. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
Bria E; Cuppone F; Ciccarese M; Nisticò C; Facciolo F; Milella M; Izzo F; Terzoli E; Cognetti F; Giannarelli D
Cancer Treat Rev; 2006 Dec; 32(8):583-7. PubMed ID: 16919884
[TBL] [Abstract][Full Text] [Related]
14. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Ng R; Loreto M; Lee R; Leighl NB
Lung Cancer; 2008 Aug; 61(2):262-5. PubMed ID: 18358559
[TBL] [Abstract][Full Text] [Related]
15. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
Langer F; Helsberg K; Schütte WH; Leschinger MI
Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
[TBL] [Abstract][Full Text] [Related]
16. Taxanes, past, present, and future impact on non-small cell lung cancer.
Joshi M; Liu X; Belani CP
Anticancer Drugs; 2014 May; 25(5):571-83. PubMed ID: 24463482
[TBL] [Abstract][Full Text] [Related]
17. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer.
Di Maio M; Perrone F; Chiodini P; Gallo C; Camps C; Schuette W; Quoix E; Tsai CM; Gridelli C
J Clin Oncol; 2007 Apr; 25(11):1377-82. PubMed ID: 17416857
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
Qi WX; Shen Z; Yao Y
Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
[TBL] [Abstract][Full Text] [Related]
19. Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trial.
Serke M; Schoenfeld N; Loddenkemper R
Anticancer Res; 2004; 24(2C):1211-6. PubMed ID: 15154649
[TBL] [Abstract][Full Text] [Related]
20. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.
Fossella FV; Lee JS; Berille J; Hong WK
Semin Oncol; 1995 Apr; 22(2 Suppl 4):22-9. PubMed ID: 7740327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]